Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Respiratory Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Respiratory Infections
    Predicting Tuberculosis Outbreaks Based on the First 2 Cases - (DGNews)
    TopAbstracts in Respiratory Infections 06/23/2008 - (DGNews)
    TopAbstracts in Respiratory Infections 06/09/2008 - (DGNews)
    TopAbstracts in Respiratory Infections 05/26/2008 - (DGNews)
    Silver-Coated Endotracheal Tubes Reduce Rates of Ventilator-Associated Pneumonia: Presented at ATS - (DGDispatch)

    News archive

     Recent webcasts/CME - Respiratory Infections
      Pharmacological Management of Coughs and Colds
      Evaluation and Management of Pneumonia in Older Adults
      The Latest on Community-Acquired Pneumonia
      Principles of Treatment of CAP - Part 2: Implications of Antimicrobial Pharmocokinetics/Pharmocodynamics
      Principles of Treatment of CAP - Part I: Implications of Antimicrobial Resistance

      Webcasts/CME archive

       Recent cases - Respiratory Infections
        Coexistence of Primary Adenocarcinoma of the Lung and Tsukamurella Pneumonia: A Case Report and Review of the Literature
        Fatal Necrotizing Pneumonia Due to a Panton-Valentine Leukocidin Positive Community-Associated Methicillin-Sensitive Staphylococcus Aureus and Influenza Co-Infection: A Case Report
        Lessons from Mycobacterium Avium Complex-Associated Pneumonitis: A Case Report
        Malaise, Weight Loss, Pleuritic Chest Pain and Productive Cough: What is Your Call?
        Rapidly Progressive Bronchiolitis Obliterans Organising Pneumonia Presenting with Pneumothorax, Persistent Air Leak, Acute Respiratory Distress Syndrome and Multi-Organ Dysfunction: A Case Report

        Cases archive
          




        my personal edition > respiratory infections > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Real-life Treatment of Acute Exacerbation of Chronic Bronchitis: Presented at ECCMID

        By Chris Berrie

        NICE, FRANCE -- April 6, 2006 -- Under the real-life treatment conditions of a physician's practice, moxifloxacin promotes faster symptom relief and higher recovery rates than other macrolides for patients with acute exacerbation of chronic bronchitis (AECB), according to a multicenter, open, prospective, non-interventional, non-randomized, observational study.

        Kathrin Stauch, project manager, Medical Science Europe and Overseas, Postmarketing Surveillance Department, Bayer HealthCare, Leverkusen, Germany, presented the data on the 8-methoxyfluoroquinolone moxifloxacin here on April 3rd at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

        AECB is known to be one of the main components in chronic obstructive pulmonary disease (COPD). There are some 3 million deaths per year caused by COPD and just over 10% of the population in Germany have chronic bronchitis.

        The objectives of this study were to compare the real-life treatment of AECB using moxifloxacin tablets or different oral macrolides, in terms of symptom relief, time to improvement/cure, and overall efficacy and tolerability.

        The researchers enrolled 464 general practice physicians throughout Germany, who were asked to record patient demographic and medical history, antibiotic treatments, severity of acute infection, and antibiotic therapy. To have a comparable baseline, patients were required to have had a macrolide agent as treatment for their most recent exacerbation of COPD.

        Across the moxifloxacin (n = 904) and total macrolides (n = 846) groups, patients' demographic characteristics were similar for, respectively: mean age, 57.4 versus 56.4 years; males, 56.4% versus 54.7%; mean body mass index (BMI), 26.6 versus 26.7 kg/m2; current smokers, 27.7% versus 29.8%. Duration of chronic bronchitis and concomitant diseases were similar in the two treatment groups.

        Patients were treated with either moxifloxacin tablets (400 mg OD) or the oral macrolides: azithromycin (n = 222; 500 mg OD in 85.1%), clarithromycin (n = 360; 500 mg OD in 71.7%) or roxithromycin (n = 264; 300 mg OD in 92%). The recommended course lengths for each of these agents were generally followed, with 5 to 10 day courses for moxifloxacin (97.7%), clarithromycin (79.5%) and roxithromycin (95.0%), and the shorter 3-5-day course for azithromycin (86.9%).

        Subjective physician assessment of disease severity was significantly worse (P <.0001) for the moxifloxacin group than the macrolides group, respectively (mild, 4.8% vs. 8.4%; moderate, 35.7% vs. 44.3%; distinct, 48.2% vs. 39.1%; severe, 9.7% vs. 5.9%).

        Time to improvement of acute exacerbation was significantly better with moxifloxacin (3.2 days) than macrolide (4.4 days; P <.0001). This was paralleled in the mean times to recovery of 6.2 days and 7.5 days, respectively (P <.0001). Total recovery rates were also significantly better with moxifloxacin than the macrolides (fever, 96.6% vs. 91.2%, P <.0001; dyspnoea, 69.0% vs. 60.2%, P =.0002; cough, 42.5% vs. 33.1%, P <.0001). Remission from purulent sputum was not significantly different between the drug treatments (98.9% vs. 98.8%, respectively).

        Although largely subjective, physicians were also asked to provide their assessments of overall efficacies and tolerabilities. Moxifloxacin was rated better than the macrolides in terms of overall efficacy (96.1% vs. 67.5%) and overall tolerability (98.1% vs. 91.7%).

        With no serious adverse effects reported for either group, the two treatments showed similar adverse reactions, which were restricted to gastrointestinal disorders.

        This physician-based study comparing moxifloxacin and other macrolides thus indicates that in the treatment of patients with AECB, moxifloxacin shows superiority for symptom relief and recovery rates, with comparable safety profiles.

        "We saw that physicians tended to use moxifloxacin more in the patients with severe AECB and in patients with more concomitant diseases, and so you can see that they used it more for the more ill patients," Kathrin Stauch commented.

        Bayer HealthCare provided financial support for this study.


        [Study title: Real-life Treatment of Acute Exacerbation of Chronic Bronchitis – Moxifloxacin Compared to Macrolides. Abstract P1055]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send